Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-01-16Clinical Trial Update: Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma [Phase 2]
This update describes a Phase 2 clinical trial evaluating selinexor in combination with DRd (daratumumab, lenalidomide, dexamethasone) for n…
-
CLINICAL_TRIALS research · 2025-01-16Clinical Trial Update: A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma [Phase 2]
A Phase 2 clinical trial evaluating venetoclax in combination with isatuximab and dexamethasone for relapsed/refractory multiple myeloma is …
-
CLINICAL_TRIALS research · 2025-01-16Clinical Trial Update: A Trial of Selinexor, Ruxolitinib and Methylprednisolone [Phase 1]
A Phase 1 clinical trial investigates a combination of selinexor, ruxolitinib, and methylprednisolone in adults with relapsed or refractory …
-
CLINICAL_TRIALS trial_result · 2025-01-15Clinical Trial Update: Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies [Phase 2]
A Phase 2 trial update reports results for pembrolizumab in relapsed or refractory multiple myeloma after anti-BCMA CAR-T therapy; the study…
-
CLINICAL_TRIALS research · 2025-01-15Clinical Trial Update: A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant [Phase 3]
A Phase 3 trial comparing two treatments in newly diagnosed multiple myeloma patients ineligible for transplant is currently ACTIVE_NOT_RECR…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-01-15Clinical Trial Update: Patient With MMRR Treated With Belantamab Mafotidine on Monotherapy
A completed clinical trial update describes a patient with multiple myeloma treated with belantamab mafotidine as monotherapy.
-
CLINICAL_TRIALS trial_result · 2025-01-14Clinical Trial Update: Determining Normal Range for Free Light Chains in Serum Among Twins [NA]
A completed UCSF clinical trial evaluated the normal range of serum free light chains in twins in the context of multiple myeloma.
-
EMA approval · 2025-01-13EMA Authorised: Pepaxti (Melphalan flufenamide hydrochloride) — Oncopeptides AB (publ)
The European Medicines Agency authorised Pepaxti (melphalan flufenamide hydrochloride) for multiple myeloma, with Oncopeptides AB (publ) as …
-
CLINICAL_TRIALS research · 2025-01-09Clinical Trial Update: Iberdomide and Daratumumab As Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma [Phase 2]
A Phase 2 trial is evaluating Iberdomide in combination with Daratumumab as maintenance therapy after autologous stem cell transplant for mu…
-
CLINICAL_TRIALS research · 2025-01-09Clinical Trial Update: A Machine Learning Approach to Connect Multiple Myeloma Complexity to Early Disease Recurrence
This clinical trial investigates a machine learning approach to link multiple myeloma complexity with early disease recurrence. It is curren…
-
CLINICAL_TRIALS trial_result · 2025-01-08Clinical Trial Update: A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM [Phase 2]
Phase 2 trial evaluating the addition of isatuximab to CyBorD induction and lenalidomide maintenance in newly diagnosed transplant-eligible …
-
CLINICAL_TRIALS trial_result · 2025-01-08Clinical Trial Update: A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma [Phase 1]
A Phase 1 safety and efficacy study evaluating CTX120 in relapsed or refractory multiple myeloma has been terminated. No results are provide…
-
CLINICAL_TRIALS research · 2025-01-08Clinical Trial Update: Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex [Phase 1, Phase 2]
This clinical trial update describes a multi-center Phase 1/2 study of belantamab mafodotin in combination with pomalidomide and dexamethaso…
-
CLINICAL_TRIALS research · 2025-01-07Clinical Trial Update: Study of CT071 Injection in RRMM or PPCL [EARLY_Phase 1]
Clinical trial update for CT071 injection in relapsed/refractory multiple myeloma and primary plasma cell leukemia; early-phase 1 study curr…
-
EMA approval · 2025-01-06EMA Authorised: Pomalidomide Viatris (Pomalidomide) — Viatris Limited
The European Medicines Agency authorised Pomalidomide Viatris for the treatment of multiple myeloma, with EU marketing authorization granted…
-
CLINICAL_TRIALS research · 2025-01-06Clinical Trial Update: Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM) [Phase 1, Phase 2]
A Phase 1/2 clinical trial assessing safety and efficacy of an anti-BCMA/FcRL5 CAR-T cell therapy for relapsed/refractory multiple myeloma. …
-
CLINICAL_TRIALS research · 2025-01-06Clinical Trial Update: Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies [Phase 1]
A Phase 1 clinical trial evaluating safety and efficacy of a fourth-generation CAR-T therapy for hematologic malignancies, including multipl…
-
CLINICAL_TRIALS research · 2025-01-06Clinical Trial Update: Longitudinal Data Registry of Plasma Cell Dyscrasia
This entry describes a longitudinal data registry study of plasma cell dyscrasias, including multiple myeloma, sponsored by Shanghai Zhongsh…
-
CLINICAL_TRIALS research · 2025-01-03Clinical Trial Update: To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM [EARLY_Phase 1]
Early-phase clinical trial evaluating the safety and efficacy of a human-derived anti-BCMA CAR-T cell therapy for relapsed/refractory multip…
-
CLINICAL_TRIALS trial_result · 2024-12-30Clinical Trial Update: Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma [Phase 2]
Phase 2 trial evaluating a daratumumab-based, response-adapted therapy for older adults with newly diagnosed multiple myeloma, with results …
-
CLINICAL_TRIALS trial_result · 2024-12-27Clinical Trial Update: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma [Phase 2]
This is a Phase 2 trial update indicating an out-of-specification (OOS) finding for JNJ-68284528 intended for commercial release in particip…
-
CLINICAL_TRIALS other · 2024-12-27Clinical Trial Update: Characteristics and Clinical Significance of Gut Microbiota in Patients With Monoclonal Gammopathy
This clinical trial examines the characteristics and potential clinical significance of gut microbiota in patients with monoclonal gammopath…
-
FDA approval · 2024-12-26FDA Approved: CYCLOPHOSPHAMIDE — Original Application (Slate Run Pharmaceuticals, LLC)
FDA approves Slate Run Pharmaceuticals' original application for CYCLOPHOSPHAMIDE FOR INJECTION, expanding the market for a generic cyclopho…
-
CLINICAL_TRIALS trial_result · 2024-12-24Clinical Trial Update: Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma [Phase 3]
Phase 3 trial comparing Daratumumab with Velcade, Lenalidomide, and Dexamethasone versus Velcade, Lenalidomide, and Dexamethasone in previou…
-
CLINICAL_TRIALS trial_result · 2024-12-24Clinical Trial Update: A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors [Phase 1, Phase 2]
An update on the Phase 1/2 study of CYT-0851 in B-cell malignancies and advanced solid tumors, noting completion of Phase 1/2 cohorts.